H. Lundbeck A/S will redirect capital investments from Europe to the US and China, citing superior innovation incentives in those markets. CEO Charl van Zyl highlighted strong recognition of innovation in the US and technological advancements in China, contrasting with Europe's lagging rewards for pharmaceutical innovation.

The Danish neuroscience-focused drugmaker holds $2-3 billion for mergers and acquisitions as it seeks to bolster its pipeline amid generic competition for Abilify Maintena outside the US. Lundbeck lost a bidding war for Avadel Pharmaceuticals to Alkermes last year, with van Zyl noting they felt the target "needed it more than we did." Trump's push for equal drug pricing globally adds complexity.

Lundbeck won't face market launch decisions until at least 2028 when it expects a new product. The company remains committed to bringing medicines to as many patients as possible while navigating ethical dilemmas around market prioritization. Its strategy reflects broader pharmaceutical industry realignment toward markets offering stronger innovation rewards.